A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Yale University, Yale Cancer Center, New Haven, Connecticut

France

Institut Bergonié, Bordeaux

Hôpital Paris Saint Joseph, Paris

Institut Gustave Roussy, Villejuif